- Home
- IVD
- By Technology Types
- By Diseases Types
- By Product Types
- Research
- Resource
- Distributors
- Company
| Product Name | D-Luciferin, Free Acid |
| Catalog No. | RESK-0266 |
| Description | D-Luciferin (free acid form) is the classic substrate of firefly luciferase and is widely used across biotechnology, especially for in vivo bioluminescence imaging (BLI). In the presence of ATP and luciferase, the substrate is oxidized and emits light; when luciferin is in excess, the photon output is proportional to the luciferase concentration. Cells transfected with a luciferase (Luc) reporter plasmid can be introduced into research animals such as rats and mice; after substrate injection, light intensity is monitored by BLI to track disease progression or therapeutic efficacy in real time. The ATP dependence of the reaction also allows bioluminescence intensity to serve as an indicator of cellular energy status or viability. |
| Intended Use | Substrate for firefly luciferase in in vivo bioluminescence imaging, in vitro reporter gene assays, and ATP-based viability/energy assays. |
| Principle / Technology | ATP- and luciferase-dependent oxidation of D-luciferin generates oxyluciferin with emission of visible light; photon output correlates with luciferase concentration when substrate is in excess. |
| Detection Method | Bioluminescence imaging (BLI) or luminometric detection |
| Sample Type | Luciferase-expressing cells and research animals (e.g., mice, rats) for in vivo imaging; cell lysates for reporter assays |
| Performance Range / Specifications | CAS No.: 2591-17-5 Synonym: (S)-4,5-Dihydro-2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid Molecular formula: C11H8N2O3S2 Molecular weight: 280.33 g/mol Appearance: Off-white to light yellow powder Purity (HPLC): >=95% Solubility: Poorly soluble in water; dissolution can be promoted with dilute base. |
| Reaction Conditions / Protocol | 1. Dissolve the free acid in a small volume of 0.1-0.5 M NaOH. 2. After complete dissolution, dilute with PBS to the required concentration and adjust the pH (e.g., to 7.4). 3. Sterilize the injectable working solution by filtration. |
| Storage Conditions | Store at -20 °C, dry and protected from light. |
| Shelf Life | 1 year when stored at -20 °C, dry and protected from light. |
| Package Specifications | 100 mg 500 mg 1 g |
| Product Form | Off-white to light yellow powder |
| Purity | >=95% (HPLC) |
| Molecular Weight | 280.33 g/mol |
| pH Range / Optimal pH | Adjust final working solution to physiological pH (e.g., pH 7.4) after dissolution in dilute base. |
| Shipping Conditions | Shipped with ice packs. |
| Recommended Buffer System | Dissolve first in a small volume of dilute base (0.1-0.5 M NaOH recommended); once fully dissolved, dilute with PBS to the desired concentration and adjust pH. |
| Application Notes / Precautions | 1. The free acid form is poorly soluble in water; unlike the ready-to-use salt forms, it requires a small amount of dilute base to dissolve. 2. Prepare sterile, injectable solutions (pH 7.4) by filtration. 3. Protect from light and moisture during storage and handling. |
For research use only, not for clinical use.
|
There is no product in your cart. |